Back to News
Market Impact: 0.2
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Source: zacks.com
Analyst InsightsAnalyst EstimatesMarket Technicals & FlowsHealthcare & Biotech
Prelude Therapeutics (PRLD) is described as technically oversold, potentially indicating that heavy selling pressure has waned. The article also cites broad agreement among Wall Street analysts in raising earnings estimates as a possible catalyst for a stock trend reversal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
PRLD0.55
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- Dow falls 189 points as AI stocks slide and oil prices surge
- Wall Street's fear gauge is ripping. Traders see it going even higher
- MSCI Ignites Indonesia Market Reckoning After Months of Warnings